{"id":"olmesartan-amlodipine-hydrochlorothiazide-if-necessary","brandName":"olmesartan/amlodipine + hydrochlorothiazide, if necessary.","genericName":"olmesartan/amlodipine + hydrochlorothiazide, if necessary.","companyId":"daiichi-sankyo-europe-gmbh-a-daiichi-sankyo-company","companyName":"Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company","phase":"marketed","status":"active","modality":"Small molecule","aliases":[],"developmentCodes":[],"firstApprovalDate":null,"firstApprovalCountry":null,"aiSummary":"Olmesartan/amlodipine/hydrochlorothiazide is a triple-combination antihypertensive marketed by Daiichi Sankyo Europe under the brand Sevikar HCT, combining an angiotensin II receptor blocker (ARB), calcium channel blocker (CCB), and thiazide diuretic. The fixed-dose combination targets hypertension through three complementary mechanisms: ARB-mediated vasodilation and aldosterone suppression, CCB-induced vascular smooth muscle relaxation, and thiazide-induced sodium/fluid reduction, enabling synergistic blood pressure reduction in resistant or difficult-to-control hypertension. Approved across Europe and multiple international markets, Sevikar HCT represents a mature, well-established therapy for patients requiring intensified antihypertensive coverage. Clinical differentiation centers on superior central aortic pressure reduction versus dual-agent comparators and convenience of single-pill therapy. Commercial significance is moderate within the crowded antihypertensive market; peak sales remain below $500M globally. Pipeline development has focused on formulation optimization and comparative efficacy studies rather than new indications.","enrichmentLevel":3,"visitCount":0,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Olmesartan is an angiotensin II receptor blocker (ARB) that prevents vasoconstriction and aldosterone release. Amlodipine is a calcium channel blocker that relaxes vascular smooth muscle. Hydrochlorothiazide is a thiazide diuretic that reduces blood volume by increasing sodium and water excretion. Together, these three agents provide synergistic antihypertensive effects.","oneSentence":"This combination blocks angiotensin II receptors, inhibits calcium channels, and reduces sodium reabsorption in the kidney to lower blood pressure through multiple complementary pathways.","_ai_confidence":"high"},"administration":{},"safety":{"commonSideEffects":[{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Hyperkalemia (with ARB component)"},{"rate":null,"effect":"Hypokalemia (with thiazide component)"},{"rate":null,"effect":"Hyperuricemia"},{"rate":null,"effect":"Peripheral edema"}]},"trials":[],"indications":{"approved":[{"name":"Hypertension (essential hypertension in patients not adequately controlled on dual therapy)"}]},"commercial":null,"patents":[],"timeline":[],"rwe":[],"competitors":[],"ownershipHistory":[],"trialDetails":[],"genericFilers":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"labelChanges":[],"nice":null,"revenue":null,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":false,"score":3}}